Return to Provider News

Information Related to NYS DFS Insurance Circular Letter No. 1 (2022)

Audience: Hospitals and Skilled Nursing Facilities

Excellus BlueCross BlueShield (BCBS) has implemented the requirements included in the New York State Department of Financial Services’ (NYS DFS) Insurance Circular Letter No. 1 (2022) issued January 6, 2022, for its commercial and Safety Net lines of business. In addition, Excellus BCBS has voluntarily extended Circular Letter No. 1 requirements to its Medicare line of business.

The requirements of Circular Letter No. 1 are not extended to the Federal Employee Program (FEP).  Some self-funded accounts may not wish to apply the terms of Circular Letter No. 1. 
We’ve summarized the provisions of Circular Letter No. 1 below; please review the entire document for full details.

Beginning January 6, 2022 through February 5, 2022 (end date subject to extension), the following provisions are in place: 

In-Network Hospital Transfers

Preauthorization requirements for in-network hospital transfers are suspended for thirty days beginning January 6, 2022.

  • The hospital should use its best efforts to provide 48 hours’ notice to Excellus BCBS after the in-network transfer, including information necessary for Excellus BCBS to assist in care coordination and discharge planning.

In-Network Inpatient Rehabilitation Services Following an Inpatient Hospital Stay

Preauthorization requirements for in-network inpatient rehabilitation services following a hospital admission are suspended for thirty days beginning January 6, 2022.

  • The hospital should use its best efforts to provide notice of the discharge to Excellus BCBS within 48 hours. 
  • Excellus BCBS may require the rehabilitation facility or skilled nursing facility to provide notification of the admission. 
  • Excellus BCBS may concurrently or retrospectively review inpatient rehabilitation services for medical necessity.

Please use the Find A Doctor tool for a list of in-network hospitals and skilled nursing facilities.

If you have any questions, please contact your Provider Relations representative

Related News
Prior Authorization Updates for Elitek®, Abraxane® & Paclitaxel Protein- Bound Particles, Neulasta® and Udenyca® Effective March 1, 2023

Prior Authorization Update for Neulasta® and Udenyca® (pegfilgrastim) Effective March 1, 2023

Expansion of Child Health Plus Benefits Effective January 1, 2023

Medicare Advantage Prior Authorization for Select Oncology Medications

CareAdvance Provider Tool Expanding to Federal Employee Program

Category

Excellus

Utilization Management

General Office Information

Updates and Reminders

 

GDPR Notification Content